Dermoscopic Evaluation of Intralesional Pentoxifylline in the Treatment of Alopecia Areata

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR202509732842066

Enrollment

Registered

2025-09-16

Start date

2023-09-12

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin and Connective Tissue Diseases

Interventions

Evaluation of Intralesional Pentoxifylline in the Treatment of Alopecia Areata by Dermoscopy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients diagnosed with AA (either patchy, ophiasis, alopecia totalis, or universalis), patients aged> 18 years, both sexes

Exclusion criteria

Exclusion criteria: pregnant and lactating females, patients having other autoimmune diseases, patients having other scalp or hair lesions, patients who had undergone systemic immunosuppressive therapy 3 months before recruitment, patients not giving consent, patients with psychological disorders patients with unrealistic expectations were excluded from the study.

Design outcomes

Primary

Measure	Time frame
Change in Severity of Alopecia Tool (SALT) Score, Dermoscopic (Trichoscopic) Evaluation of Regrowth	—

Secondary

Measure	Time frame
Clinical Assessment (Target lesion regrowth and patient satisfaction	—

Countries

Egypt

Contacts

Public ContactMofreh Ismail

professor of Dermatology Venereology and Andrology

mofrehmansour@gmail.com+201003344887

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026